Hubungan Soluble Vascular Cell Adhesion Molecule-1 dengan Asam urat dan Magnesium pada pasien chronic kidney disease
DOI:
https://doi.org/10.36408/mhjcm.v7i1.431Keywords:
CKD, LFG, sVCAM-1, asam urat, magnesiumAbstract
Latar belakang: Kondisi Chronic kidney disease (CKD) dapat terjadi proses inflamasi dan aterosklerosis akan melibatkan marker inflamasi, disfungsi endotel Soluble vascular cell adhesion molecule-1 (sVCAM-1), asam urat (AU) dan peran elektrolit magnesium berhubungan dengan patofisiologi CKD .sVCAM-1 merupakan biomolekuler marker inflamasi dan disfungsi endotel, AU sebagai marker inflamasi dan magnesium berperan dalam metabolisme elektrolit ginjal.
Tujuan: Membuktikan hubungan antara sVCAM-1 dengan asam urat (AU) dan magnesium (Mg) pada pasien CKD.
Metoda Penelitian: Penelitian belah lintang dilakukan pada 33 penderita CKD belum pernah hemodialisis, sampel diambil selama bulan Maret - Juni 2019. Nilai Laju Filtrasi Glomerulus (LFG) dihitung menggunakan rumus Cockcroft-Gault. Kadars VCAM-1 diperiksa menggunakan metode Enzyme Link Immunosorbent Assay. Kadar asam urat diperiksa dengan metode fotometrik enzimatik dan magnesium diperiksa dengan kolorimetrik Xylidil blue menggunakan alat Advia. Uji hubungan menggunakan uji Pearson untuk data normal dan Spearman’s untuk data tidak normal.
Hasil: Nilai LFG pada penelitan ini 46,48 ± 11,44 ml/min/1,73m2. Median kadarVCAM-1 adalah 715 (564 – 991) ng/dL. Median kadar asam urat adalah 9,2 (7,8 – 15,2) mg/dL dan median untuk kadar magnesium 1,03 (0,79 – 1,5) mmol/dL. Hubungan sVCAM-1 dengan kadar asam urat serum didapatkan korelasi dengan r = 0,488 dan p = 0,004.Terdapat hubungan sVCAM-1 dengan kadar magnesium serum dengan r = -0,442; p = 0,010.
Simpulan: Terdapat hubungan positif sedang antara sVCAM-1 dengan asam urat serum, terdapat hubungan negatif sedang antara sVCAM-1dengan magnesium serum.
Kata kunci :CKD,LFG, sVCAM-1, asam urat, magnesium
Background: Chronic kidney disease (CKD ) is a condition that occurs because of the inflammatory process and atherosclerosis thus involve the marker of inflammation, endhothelial dysfuntion Soluble vascular cell adhesion molecule-1(sVCAM-1), uric acid (UA) and magnesium, associated with the pathophisiology of CKD. VCAM-1 is a marker of inflammation and endhothelial dysfuntion, UA as a marker of inflammation and Mg plays a role in renal electrolytes metabolism.
Objective: To prove the relationship between the sVCAM-1 and uric acid (UA) and magnesium (Mg) levels in CKD patients
Methode: A cross sectional study conducted on 33 patients with chronic kidney disease who had never hemodialysis during March-June 2019. Value of Glomerular Filtration Rate (GFR) is calculated using the Cockcroft-Gault formula which necessary creatinine levels. Value of GFR is calculated using the Cockcroft-Gault formula.sVCAM-1 levels were examined using the Enzyme Link Immunosorbent Assay method. Uric acid were axamined enzymatic photometric and magnesium levels were examined Xylidil blue colorimetric methods by Advia. Pearson correlation test using the test for normal data and Spearman's when data is not normal.
Results: The value of this study GFR at 46.48 ± 11.44 ml/min/1,73m2. Median levels of sVCAM-1 was 715 (564 to 991) ug / dL. Median for uric acid is 9.2 (7.8 to 15.02) mg/dL and magnesium 1,03 (0,79 – 1,5) mmol/dL There is a significant correlation between VCAM-1 with serum uric acid levels showed a correlation with(r = 0.488; p = 0.004). There is a correlation between sVCAM-1 and serum magnesium(r = -0.442; p = 0.010).
Conclusion: There is a moderate positive correlation between sVCAM-1 with uric acid serum, there is a moderate negatif correlation between sVCAM-1 and serum magnesium.
Keywords: CKD, GFR, sVCAM-1, uric acid, magnesium.
Downloads
References
2. Prodjosudjadi W, Suhardjono, Suwitra K. Detection and prevention of chronic kidney disease in Indonesia: initial community screening. Nephrology 2009:14(7):669-74.
3. Mary M, Eli AF, Barbara GD, Samy IM & Moro OS, Chronic kidney disease in the elderly: evaluation and management, Future Medicine Ltd Clin. Pract. 2014; 11(5):525–35
4. Restu P, Woro S, Faktor Risiko Gagal Ginjal Kronik Di Unit Hemodialisis RSUD Wates Kulon Progo,majalah farmaseutik,ugm,2015;11(2):316-20
5. Robinson BE. Epidemiology of chronic kidney disease and anemia. J Am Med Dir Assoc. 2006 Nov;7(9 Suppl):S3-6;quizS17-21
6. Badan Penelitian Dan Pengembangan Kesehatan Kementerian Kesehatan RI. Riset Kesehatan Dasar (RISKESDAS). 2013. (Accessed at http://terbitan.litbang.depkes.go.id/penerbitan/index.php/blp/catalog/book/64)
7. CKD in United States, USRDS Annual Data Report, 2015;1:S1-20
8. Wahyudi IED, Pujo JL. Angka kematian pasien end stage renal disease di ICU DAN HCU RSUP DR. Kariadi. MMM. 2013;1
9. Situasi Penyakit Ginjal Kronis 2017, Pusat Data Dan Informasi Kementerian Kesehatan RI, 2017;(8): hal 9-10
10. Perhimpunan Nefrologi Indonesia (PERNEFRI). 8th Report Of Indonesian Renal Registry, 2016:h4-6
11. Cybulsky M, Fries JW, Williams AJ, Sultan P, Eddy RL, Byers MG, Shows TB, Gimbrone MA Jr, Collins T (1991). "The human VCAM1 gene is assigned to chromosome 1p31-p32". Cytogenet. Cell Genet. 58(3–4): 1852. doi:10.1159/000133735.
12. Lu S, Ge M, Zheng Y, Li J, Feng X, Feng S, et al. CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-?B in the bone marrow failure of acquired aplastic anemia. Stem Cell Research & Therapy (2017) 8:178 DOI 10.1186/s13287-017-0620-4.
13. Martin H, Hu J, Gerhard G. Impaired endothelial function and increased carotid stiffness in 9 years old children with low birthweight. Circulation 2010;102:2739-44.
14. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest. 2001;107(10):1209-10
15. Maitra A, Abbas AK. The Inflammation System. In : Kumar V, Abbas AK,Fausto N. Robbins and Cotran Pathologic Basis of Disease. 2005; 7:1155-226.
16. Suliman M.E, Jonshon RJ, Garcia LE, Qureshi AR Molinaei H, Carrero JJ,. J-shaped mortality relantionship for uric acid in CKD. Am. J Kidney Dis 2006:48(5):761-771.
17. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int. 2014;85(1):174–81.
18. Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU, et al. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol. 2012;36(3):228–37.
19. Ansari MR, Maheshwari N, Shaikh MA, Laghari MS, Darshana, Lal K, et al. Correlation of serum magnesium with dyslipidemia in patients on maintenance hemodialysis. Saudi J Kidney Dis Transpl. 2012;23(1):21-5.
20. Perico N. Chronic kidney disease: a research and public health priority. Nephrol Dial Transplant 2012;10: 1-8.
21. Kyriakos L, Vianda S., Inflammation, Endothelial Dysfunction and increased left ventricular Mass in CKD patients : a longitudinal study, PLOS ONE, 2015;10(9): e0138461
22. Dharma, PS. Penyakit Ginjal Deteksi Dini dan Pencegahan. Yogyakarta: CV Solusi Distribusi,2014.
23. Hidayati T, Kushadiwijaya H, Suhardi. Hubungan antara Hipertensi, Merokok dan Minuman Suplemen Energi dan Kejadian Penyakit Ginjal Kronis. Berita Kedokteran Masyarakat 2008:24(2)
24. Feig DI., Uric acid a novel mediator and marker of risk in chronik kidney disease. Curr Opin Nephrology Hipertens. 2009;18(6):526-30
25. Mazzali M, Hughes J, Kim YG, Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101–6
26. Floege J.Magnesium in CKD:more than a classification inhibitor.J Neprol.2015;28:267-77
27. Gosh AK, Joshi SR. Disorder of calcium, phosphorus, and magnesium metabolism. JAPI. 2008;56:613-21
28. Noronha JL, Matuschak GM. Magnesium in critical illnes: metabolism, assesment, and treatment. Intensive Care Med. 2012;28:667-79
29. Jeanette AM, Maier A, Corinne M. Low magnesium promotes endhothelial cell dysfunction : implication for atherosclerosis, inflammation and thrombosis. Biochemica et Biophysica Acta (BBA). 2004: 2124(13):13-21
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2020 Medica Hospitalia : Journal of Clinical Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
